Featured Articles

31. Day One Bio Aims To Shorten The Time Gap On Cancer Treatments For Kids 2/7/2025

    Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the recent sunset of the FDA's rare pediatric disease Priority Review Voucher program.

32. The Spark Of Change In Healthcare's 2024 Investment Ecosystem 2/6/2025

    Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven strategies, have set the healthcare and biotech industries on a positive trajectory for 2025, writes Joseph Pategou.

33. Companies To Watch: Senti Bio 2/5/2025

    Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.

34. How Pharma Can Best Manage Third-Party Risk 2/4/2025

    Experts at Crowe Life Sciences offer tips for effectively managing risk associated with third parties such as clinics, retail pharmacies, health information system providers, and independent research organizations.

35. Advancements In GLP-1 Analog Formulation Development: Overcoming Challenges In Oral Delivery 2/3/2025

    Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and adherence while expanding the therapeutic market.

36. Rethinking Global-To-Local Pricing And Market Access For Pharmaceuticals 1/31/2025

    Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access strategies, from core markets to the local affiliate level in non-core markets.

37. Biopharma R&D Faces Productivity And Attrition Challenges In 2025 1/29/2025

    Evaluate VP of Thought Leadership Daniel Chancellor discusses trends for 2025 as the surge in R&D, coupled with rapidly evolving industry dynamics, presents a productivity and attrition challenge for the industry.

38. Court Ruling Alters the Calculus for Orange Book Patent Listings 1/23/2025

    Recent court rulings have changed the way branded and generic drug manufacturers should think about patent listings in the FDA Orange Book. Hatch-Waxman experts at Polsinelli detail the changes and implications, and make predictions about what comes next.

39. Automation And Digital Solutions Can Help You Reach Your mRNA Manufacturing And Sustainability Goals 1/14/2025

    Explore how digital solutions help streamline mRNA manufacturing by reducing costs, improving efficiency, and supporting sustainability by creating paperless processes for emerging therapeutics.

40. Unlocking The Potential Of AI In Pharma: The Power Of Data Systems 1/10/2025

    Clean, humanized data and data systems are the crucial fuel for engines driving new AI capabilities and uses across the biopharmaceutical industry. Data integrity, accessibility, and ethical use of data are prerequisites for turning data systems and AI into trusted allies.